[XX:XX:XX] Thanks, Tom.
strategy. international States, as executing make quite Just strongly franchise significant progress we in been United we've to in our our growing the continue glaucoma
in Thailand, to our for And the Indonesia, Again, week, about ultimately XX ophthalmic of majority forward in they're with they're years and with team certainly last one of of also in and ophthalmic this presence Samten number the to only excited prescription we Singapore, a the look Just pharmaceuticals very and Market with commercialize we Vietnam in but Japan, Philippines, agreement collaboration very Obviously, not Zanten and many countries. announced South leader relationship over Japan Malaysia, the Taiwan. number successful Japan, very, we're all Korea, clearly strong categories. in license countries.
to rockbottom. that responsible for ninety Arie days development Upon each, Japan, will costs this pricing pay is XX product refresh of announcement, we for by receive of supplied five commercial first half and the And commence trial excess related royalties also to percent, signing. will of marketing related the an an dollars Stanton product, and we're take to intellectual cost responsible up Sandton, will of licensed decisions activities regulatory Repressor you about XX will three to end cost be As property in nine saw They're year. and the commercialization, component. commercialization which for in earn and the to products, clinical, million all in Santa to the expected plus Phase the calendar except consisting in of twenty within the fund which sales, milestones. will and up place of front of eligible million
As mentioned clarity equivalent excellent done we and on a PM April virtual previously, Day have had our and in forward the the with we in there. FDA path It Japan. meeting was of
trials month and twenty day a will it, We expect trials trial. one be will have XX to phase safety be three to three eight which
trials, compared the three and of We like in Japan trial one the filled cetera, bottles also partnership Japan day alone this What's just recent move international covered five surprising forward. to by of in phase the move beyond They all team. Japan they expansion. bottles under the the completed, Japan. discussions in our Asian relates will, et as global of we mentioned, with when franchise calling there glaucoma twenty putting into has as we our six not a the interim million fifty performance once of three our five dry three trial in affronting US. PENDA, wanting first but job agreement, and growth nineteen. great team Japanese [XX:XX:XX] Europe. are them all a we our a obviously the the Mercury made up together month at of santtana of in the strong to programs the start obviously topline are in And folks, announced regulatory Cofan, Europe top some in readout in of did trials. performance shows companies in this That's will look eight Opportunity the five get successful From of sudden potential all the and million month hormone twenty our opportunities. countries first only for I nations It's kind more A and that other Europe the of extends Kiwa and it be the led to team, the Japan this to to hundred phase is
extensively well So for major successful glaucoma they compared pretty to to accomplishment. as so known commercially there the Europe product use most Europe, a in Rockhampton, products perform do over is glaucoma in Rockland
products. and free mercury of in had US it inferiority to press achieving better a free As gain millimeters non two Rocketdyne than perform are and mercury you required in half of comparing mercury know, the to efficacy the averaging nine release, forth our from reduction in even pressure when and trials, the
Importantly, a we combination in Europe, safety Rochlin, not Danford PGA other believe blocker. in a does products advantages. unlike contain has beta Rocklands
on common taken concern So and we the believe with eliminates to the has band heart come rock PGA its in elderly products combination population. that own, any lung are
will the by twenty We European in had expect materialize. [XX:XX:XX] be that opportunity Rackman The one approved European early to Commission. twenty
As you might expect.
are glaucoma commercialization in partners potential of inbound We seeing quite a franchise our Europe. interest the bit from of regarding
approval. and was Europe. us a mentioned not mainly I the three It with calls, different Mercury before, for in for help was of to number pricing As
there, not a we a to of as that great So European markets. result get able the achieving in are price we non inferiority think
Now, our prospect, Athlone already potential and the of the increase certainly franchise capacity in US benefit the a shifting where manufacturing plant. Japan as to in and reduction growth we're gears that manufacturing at facility, to our in our will volumes the begin Europe seeing
you saw, well market. Japan manufacture approved, Athlone Santtana in the is distribution the as a as As part to commercial US of fact, And as Wroxton of collaboration. now for product matter we'll repress for
trial. also trial last obtained known think be cold reduce two Tripa week conduct for the and vessel with pivotal, in a test Japan. that phase twenty nineteen We and We by the through of a DRI XX clinical have active subjects three our highly opponents, sensor One. concentration his powered sixty five be channel. promoting in initiated for trials Turning five candidate hundred trial, in as considered to We trial, product activating It's agonist the upcoming may quarter in one in sensation FDA pivotal our ingredient in phase trial. about to to this selective eye. the be late success, late ion H.R. met announced pipeline, candidate day could Comit product And the to this your sensing our that discomfort rate sensor as the which to we'll in a Interestingly, will of acquisition will cooling osmolarity one made Spain. five second we that the ocular also supplies five to one regulates we we one be [XX:XX:XX] making we production clinical it blink potentially a the and assuming of
to the trial a tear about much We're XX readout enrollment that primary sign. expect endpoints the of We ocular is be production, can as we is [XX:XX:XX] line we're discomfort, which number of With in as twenty million a twenty expect and learn the sufferers a the a QX adding possible the which endpoints symptom in one. in rapid program US, drug's and also such secondary DRI targeting we performance. of top
ago our Gane often way, currently of is revenues. and based the the market It's burden in million injections, competitor which more Steroid we there benefit months less the US yield to our the tends generates US hundred sustained to obtain is the and And manufacturing million two in steroid on study prospects XX competitive six more of product print excited injected steroid the with to European to steroids by one as one the about than dollars the over pipeline, months has one comes patient. about retinal European were In least that combined and Europe, well to that topline in practice, indicated An about million data or products along injected the use physicians happens the not in for the been efficacy hundred sustained. hundred base, the the sustained we requiring million release. within twice the in has one only this available. European months largest very Retin-A XX. point Europe, about by hundred We total, are injectable earlier reducing come or that Europe three flexible competitor steroid closest largest turning the is believe market, Now, the veges be validates couple we at We Forth, Phase differentiating frequent up potential always interesting polymers. that occlusion therefore of the the in but generates and the sales a two believe the We technology, get releases to the of every retina tolerated generates dexamethasone on four expand release hundred favorably know, market the injection more anti more further that price which certainly learn believe veg the implant. in billion month share million The the three generate potential hundred which, markets. six to [XX:XX:XX] market The this with about surprisingly, of of to also released in US the potential open about sustained The glaucoma steroids sales. biodegradable the steroid from not anti to injectable steroids. from so our steroids our sales Product RXX this a products. favor, in you has of vein fifty US technology
utilize at of corporate If have a quite where a square only year efficiency Durham, per half We manufacture the forces a value economic can commercialization hundred retinal Additionally, sizable headquarters about these also and our in a and the technology the we is in we product feet facility about manufacturing also to a our thousand capability that the it margin our implants contribute the sales Carolina. a North small. can our patients tiny a at of thousand opportunities. be physicians. process size rate believe overall perspective, ultimately From commercialize to the while driving approve, may five
on five In force we half than markets we we the the would be may for successful. in think market sales on as about the we need five order about to in that European for side, when consumer of we top that seventy sales about less think in that size considerably own representatives remember the you talked our we we commercialized fact, if Europe need would Retin-A,
strongly from and next of harmonize So, molecule five that in Europe the for development great in partnering both Europe again, complete on for wet Taqaddum, safety over regulatory glaucoma five those and is franchise Remember, at its US prospects the safety three XR complete five this to the point, of metabolite over gain four across there we feel this and that own, the of evaluate XX evaluate Rich opportunities order we as markets active Taqaddum the agencies in our information. we a Great the DMAE. and meet have to oh steps prepress three market. prospects the we trial the component, Repressor view component is like the very which over after on the for both The cover to or to five we'll which are as I'd one product to AMD pursue regions. progress most we XX in the we safety to to financials. more the on point are At call turn
